A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.
about
Toxin-based therapeutic approachesPossible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellInter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.The predictive significance of CD20 expression in B-cell lymphomas.Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma.Soluble CD22 as a tumor marker for hairy cell leukemia.Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.The role of monoclonal antibodies in the treatment of lymphomas.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphomaSIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.Combination therapy with the type II anti-CD20 antibody obinutuzumab.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsAntitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
P2860
Q27013664-99548EC7-E5A2-4A6D-BD7E-6912870C1BC8Q33683659-4748F8BB-02BD-42A3-9255-BC85F4443A96Q34147379-C30BA1D6-E426-4AC3-B7F4-56C536C9DA89Q34227769-37274D82-D564-422F-AE09-531CA5F4064BQ34454573-2BEB5014-5603-4907-A8A0-0461655A6584Q34870986-C7142AAA-0BCB-43F0-A682-BEB90D7D671CQ36719078-E7C065EE-DD20-4B0B-BCC5-D6933D3F9C20Q36868716-D9B465BD-9815-4D6C-A25B-DBF239329188Q37212272-914DEC42-FEA7-43EA-B75A-737B5318136AQ37334787-EFE3A4FF-9A5C-49E7-963A-D0A4471EBE0AQ37348420-00C573B1-293B-4D0C-A763-CB072F17904EQ38069595-CC3595E7-0958-4376-A50B-FE7A3D9D0632Q38087390-3C231124-14AC-4822-BB8A-92142EEF1FC4Q39204394-F90105DD-038B-49AA-A38F-3C5B92966840Q39397717-07CE6B85-95EF-47CE-8050-72DDD701AA3AQ39631034-ACC82083-1AD1-4E3C-935B-F88BF34A115CQ40971778-78974D4E-3930-4CC1-85A7-96E82D44E87EQ40996964-0C732DA6-9CB4-4814-988E-2F6735C20FDDQ41475288-6E7117D0-F4E5-452F-A063-5BB72AD51845Q41645565-20F20748-D64A-4B2E-896F-6AAE18DAE2BFQ42315730-3672A064-70C0-4548-B32C-69A7BB02B88CQ47898168-CBFFF1E3-66B4-4E08-97EA-9F839B921087Q48272279-F8395EED-17B5-4404-8AE8-3A7D448473BBQ49999453-4F0E148B-7490-43AA-9D7E-AFB1BE9A8A0EQ57174193-22D468FE-4434-4F08-AF26-741C28283B16Q58742957-225F4482-9F15-476F-ACA2-AF9164C3D32A
P2860
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A quantitative exploration of ...... gnancies using flow cytometry.
@en
type
label
A quantitative exploration of ...... gnancies using flow cytometry.
@en
prefLabel
A quantitative exploration of ...... gnancies using flow cytometry.
@en
P2093
P2860
P1476
A quantitative exploration of ...... ignancies using flow cytometry
@en
P2093
Carleton C Stewart
Kathleen Donohue
Myron S Czuczman
P2860
P304
P356
10.1080/08820130500496878
P577
2006-01-01T00:00:00Z